Angiotensin receptor blockers for heart failure

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 3, 2012, Pages

  Heran, Balraj S ^a   Musini, Vijaya M ^a   Bassett, Ken ^a   Taylor, Rod S ^b   Wright, James M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC DISEASE; DRUG COMBINATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HOSPITALIZATION; HUMAN; MALE; META ANALYSIS; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84864069565     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003040.pub2     Document Type: Review

References (86)

1. Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJV, Dargie HJ. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACEI inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. American Heart Journal 2001;141(5):800-7. x-wiley/crsRef/16449928
2. Matsumori A. Efficacy and safety of oral candesartan cilexitil in patients with congestive heart failure. European Journal of Heart Failure 2003;5:669-77. x-wiley/crsRef/16449930
3. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:762-71. x-wiley/crsRef/16449932
4. Weir RAP, McMurray JJV, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. European Journal of Heart Failure 2008;10:157-63. x-wiley/crsRef/16449933
5. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6. x-wiley/crsRef/16449935
6. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Östergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81. x-wiley/crsRef/16449937
7. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91(3):691-7. x-wiley/crsRef/16449939
8. Klinge R, Polis A, Dickstein K, Hall C. Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. Journal of Cardiac Failure 1997;3(2):75-81. x-wiley/crsRef/16449940
9. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. American Journal of Cardiology 2000;85:187-92. x-wiley/crsRef/16449941
10. Weber M. Clinical safety and tolerability of losartan. Clinical Therapeutics 1997;19(4):604-16. x-wiley/crsRef/16449942
11. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. Journal of the American College of Cardiology 1995;26(2):438-45. x-wiley/crsRef/16449944
12. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. American Journal of Cardiology 2000;85:187-92. x-wiley/crsRef/16449945
13. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In the Elderly Study, ELITE). Lancet 1997;349:747-52. x-wiley/crsRef/16449947
14. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. American Journal of Cardiology 2000;85:187-92. x-wiley/crsRef/16449948
15. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7. x-wiley/crsRef/16449950
16. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-2. x-wiley/crsRef/16449952
17. Willenheimer R, Helmers C, Pantev E, Rydberg E, Lofdahl P, Gordon A. Safety and efficacy of valsartan versus enalapril in heart failure patients. International Journal of Cardiology 2002;85:261-70. x-wiley/crsRef/16449954
18. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine 2008;359(23):2456-67. x-wiley/crsRef/16449956
19. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121:1393-405. x-wiley/crsRef/16449957
20. Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, Ney DE, Makris L, Chang PI. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. Journal of the American College of Cardiology 1997;30(4):983-91. x-wiley/crsRef/16449959
21. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. American Journal of Cardiology 2000;85:187-92. x-wiley/crsRef/16449960
22. Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, Orlov VA, Olbinskaya LI, Bolshakova TD, Sullivan J, Spormann DO. Valsartan in heart failure patients previously untreated with an ACE inhibitor. International Journal of Cardiology 1998;65:239-46. x-wiley/crsRef/16449962
23. Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, Kiowski W, Marks DS, Alegria E, Dukat A, Lenz K, Arens HA. Acute and 3-month treatment effects of candesartan cilexitil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. American Heart Journal 2003;145(3):D1-D9. x-wiley/crsRef/16449964
24. Dunselman PHJM. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. International Journal of Cardiology 2001;77:131-8. x-wiley/crsRef/16449966
25. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64. x-wiley/crsRef/16449968
26. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. American Journal of Cardiology 2000;85:187-92. x-wiley/crsRef/16449970
27. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. American Journal of Cardiology 2000;85:187-92. x-wiley/crsRef/16449972
28. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA. Randomized trial of candesartan cilexitil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. American Heart Journal 2000;139:609-17. x-wiley/crsRef/16449974
29. Riegger GAJ, Bouzo H, Petr P, Munz J, Spacek R, Pethig H, von Behren V, George M, Arens HJ. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexitil. Circulation 1999;100:2224-30. x-wiley/crsRef/16449976
30. Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, Block AJ. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. International Journal of Clinical Practice 2000;54:11-8. x-wiley/crsRef/16449978
31. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001;345:1667-75. x-wiley/crsRef/16449980
32. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658-64. x-wiley/crsRef/16449982
33. Belousov IB, Upnitskii AA, Khanina NI. [Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure]. Kardiologiia 2005;45:26-32. x-wiley/crsRef/16449984
34. Berezin AE. Angiotensin-II receptor antagonist losartan dose-dependently improves the left ventricular remodelling in patients with congestive heart failure. Journal of Clinical & Basic Cardiology 2002;5(Issue 1):83-6. x-wiley/crsRef/16449986
35. Berezin AE. Losartan in the therapy of heart failure patients. Asian Cardiovascular & Thoracic Annals 2001;9:302-7. x-wiley/crsRef/16449987
36. Blanchet M, Sheppard R, Racine N, Ducharme A, Curnier D, Tardif JC, Sirois P, Lamoureux MC, De Champlain J, White M. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure. American Heart Journal 2005;149:938.e1-7. x-wiley/crsRef/16449989
37. De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrari R, Rizzon P, Pitzalis MV. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. American Heart Journal 2003;146:E17. x-wiley/crsRef/16449991
38. Ellis GR, Nightingale AK, Blackman DJ, Anderson RA, Mumford C, Timmins G, Lange D, Jackson SK, Penney MD, Lewis MJ, Frenneaux MP, Morris-Thurgood J. Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress. European Journal of Heart Failure 2002;4:193-9. x-wiley/crsRef/16449993
39. Guazzi M, Palermo P, Pontone G, Susini F, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. American Journal of Cardiology 1999;84:1038-43. x-wiley/crsRef/16449995
40. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GAJ, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374(9704):1840-8. x-wiley/crsRef/16449997
41. Konstam MA, Poole-Wilson PA, Dickstein K, Drexler H, Justice SJ, Komajda M, Malbecq W, Martinez FA, Neaton JD, Riegger GAJ, Guptha S. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor. European Journal of Heart Failure 2008;10:899-906. x-wiley/crsRef/16449998
42. Hikosaka M, Yuasa F, Yuyama R, Mimura J, Kawamura A, Motohiro M, Iwasaki M, Sugiura T, Iwasaka T. Candesartan and arterial baroreflex sensitivity and sympathetic nerve activity in patients with mild heart failure. Journal of Cardiovascular Pharmacology 2002;40:875-80. x-wiley/crsRef/16450000
43. Houghton AR, Harrison M, Cowley AJ, Hampton JR. Combined treatment with losartan and an ACE inhibitor in mild to moderate heart failure: results of a double-blind, randomized, placebo-controlled trial. American Heart Journal 2000;140:e25. x-wiley/crsRef/16450002
44. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. Journal of Nuclear Medicine 2003;44:884-90. x-wiley/crsRef/16450004
45. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology 2005;45(5):661-7. x-wiley/crsRef/16450006
46. Ki HL, Myung HJ, Young KA, Woo SL, Dae HJ, Jeong GC, Jong CP, Jung CK, Seok KO, Nam HK, Kyung HY, Nam JY, Moon Y, Jay YR, Ji HL, Seong HJ, Ok YP, Seung UL, Dong GK. [The comparative clinical effects of valsartan and ramipril in patients with heart failure]. Korean Circulation Journal 2008;38:101-9. x-wiley/crsRef/16450008
47. Nakamura M, Saito S, Yoshida H, Arakawa N, Sugawara S, Hiramori K. Effects of chronic subdepressor dose of angiotensin II type 1 receptor antagonist on endothelium-dependent vasodilation in patients with congestive heart failure. Journal of Cardiovascular Pharmacology 2002;40(3):411-9. x-wiley/crsRef/16450010
48. Parthasarathy HK, Pieske B, Weisskopf M, Andrews CD, Brunel P, Struthers AD, MacDonald TM. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure 2009;11:980-9. x-wiley/crsRef/16450012
49. Skvortsov AA, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Mareev V, Belenkov N. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)]. Terapevticheski Arkhiv 2005;77(8):34-43. x-wiley/crsRef/16450014
50. Skvortsov AA, Nasonova SN, Sychev AV, Orlova A, Baklanova NA, Masenko VP, Mareev V, Belenkov N. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study]. Kardiologiia 2006;46:33-51. x-wiley/crsRef/16450015
51. Tang B, Sun H, Ma Y. Effect of losartan and captopril on congestive heart failure. Journal of Xingjiang Medical University 2003;26(5):424-6. x-wiley/crsRef/16450017
52. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. Journal of the American College of Cardiology 2000;35(3):714-21. x-wiley/crsRef/16450019
53. Vaile JC, Chowdhary S, Osman F, Ross HF, Fletcher J, Littler WA, Coote JA, Townend JN. Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure. Clinical Science 2001;101:559-66. x-wiley/crsRef/16450021
54. Vizir VA, Berezin AE. [Losartan in therapy of chronic heart failure]. Klinicheskaia Meditsina 2000;78(2):36-9. x-wiley/crsRef/16450023
55. Vizir VA, Berezin AE. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure]. Terapevticheski Arkhiv 2002;74(1):52-5. x-wiley/crsRef/16450025
56. Ye JF, Liu DS. Effects of benazepril combined with valsartan on congestive heart failure. Journal of First Military Medical University 2005;25(11):1441-2, 1447. x-wiley/crsRef/16450027
57. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. Focused Update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
58. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
59. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 antagonists. Circulation 2004;109:2492-9.
60. Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, Heckman GA, Howlett JG, Ignaszewski A, Johnstone DE, Jong P, McKelvie RS, Moe GW, Parker JD, Rao V, Ross HJ, Sequeira EJ, Svendsen AM, Teo K, Tsuyuki RT, White M, Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology 2006;22(1):23-45.
61. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 9-13-1997;315(7109):629-634. [MEDLINE: 90212]
62. Erhardt LR. A review of the current evidence for the use of angiotensin receptor blockers in chronic heart failure. International Journal of Clinical Practice 2005;59(5):571-8.
63. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal 2008;29:2388-2442.
64. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355(9215):1575-81.
65. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No: CD003823. [DOI: 10.1002/14651858.CD003823.pub2]
66. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No: CD003822. [DOI: 10.1002/14651858.CD003822.pub2]
67. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: The Cochrane Collaboration. Available from www.cochrane-handbook.org: Wiley-Blackwell, 2011.
68. Jong P, Demers C, McKelvie RS, Liu P. Angiotensin receptor blockers for heart failure. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No: CD003040. [DOI: 10.1002/14651858.CD003040]
69. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. Journal of Cardiac Failure 2008;14(3):181-8.
70. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Annals of Internal Medicine 2004;141:693-704.
71. Lefebvre C, Manheimer E, Galnville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Vetsion 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
72. Mancia G, Corrao G. Targeting blood pressure in the management of total cardiovascular risk. European Heart Journal Supplements 2009;11(Supplement F):F27-32.
73. McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89.
74. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown Jr EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. New England Journal of Medicine 1992;327(10):669-77.
75. Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Journal of Cardiac Failure 2010;16(3):260-7.
76. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Am J Cardiol 2000;85(2):187-192. [MEDLINE: 84]
77. Shibata M C, Tsuyuki R T, Wiebe N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. International Journal of Clinical Practice 2008;62(9):1397-402.
78. Smith DHG. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68(9):1207-25.
79. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine 1992;327:685-91.
80. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 1991;325:293-302.
81. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auglert L, Pauly NC, Aliot E, Persson S, Camm AJ. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 1995;333(25):1670-6.
82. Volpe M, Toccia G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. Journal of Hypertension 2009;27(5):941-6.
83. Weber M. Clinical safety and tolerability of losartan. Clinical Therapeutics 1997;19(4):604-16.
84. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011;57:413-20.
85. Wolny A, Clozel J, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circulation Research 1997;80:219-27.
86. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: Meta-analysis of randomized controlled trials. Journal of the American College of Cardiology 2002;39(3):463-70.